INTRODUCTION
Immunization is a cornerstone of public health through the prevention of infectious diseases and their complications.1,2Prior to the introduction of vaccines, common infectious diseases were the leading cause of mortality worldwide.3,4It is estimated that between 2 and 3 million deaths are prevented each year because of immunization.1Despite this, vaccine-preventable diseases remain a global public health concern, with most jurisdictions falling below their immunization coverage goals.5,6,7
Several strategies have been suggested to enhance vaccination coverage, including the use of non-traditional vaccine providers (i.e. providers other than family physicians and public health nurses).8,9Pharmacists, as accessible and trusted health care professionals, are in an ideal setting to fulfill multiple roles (such as educator, facilitator or immunizer) in the fight against vaccine-preventable disease.10,11Recommendations to receive immunizations by a pharmacist have been shown to have a positive impact on a person’s decision to be immunized.12
While pharmacists have functioned as immunizers in the United States since 1996, the scope of pharmacy practice in Canada began to expand to include administration of drugs, including immunizations, more recently, starting in 2007 in Alberta.13,14,15Legislation in New Brunswick (NB), Canada enabled pharmacists, with appropriate training and a permit, to begin immunizing in 2009 (initiation in practice in 2010), making it the first province in the Maritime provinces of Canada to permit pharmacists to immunize, joining pharmacists in Alberta and British Columbia (2009).16,17Legislation in New Brunswick allowed for the administration of most vaccines (including yellow fever with appropriate training) and injectable medications to those 5 years of age and older; however, remuneration for services were only reimbursed by the provincial government for the provision of influenza vaccines to those meeting specific criteria (e.g. over 65 years of age). The inclusion of pharmacist immunizers in the US has shown benefits, supporting the expanded scope of pharmacy practice to include immunization.18,19,20Studies have demonstrated increased influenza vaccination coverage rates in states allowing pharmacists to immunize versus those that did not, although some of the studies had methodological concerns.21,22American pharmacists initially focused on provision of seasonal influenza vaccinations, gradually addressing other vaccination needs with time and experience.23,24
While American pharmacists have had successes as immunizers, they have also faced challenges. Although most licensed US pharmacists are trained to administer vaccines, they face numerous barriers such as time, space and concerns about liability and reimbursement.23,25,26Conversely, several facilitating factors have been identified as important, including support from management, year-round immunization programs to maintain competencies, and increasing the number of immunizers in a practice site.27
As immunization administration is more recent for Canadian pharmacists, limited data is available on their perspective on their experiences, and there is no data from any of the Maritime provinces, where pharmacists are thought to fill gaps due to shortages of primary care providers.28,29,30,31The aim of the study was to determine which vaccines pharmacists in New Brunswick, Canada are providing, and to identify barriers and facilitators associated with immunizing to inform continuing education and practice policy.
METHODS
Study Design and Participants
A web-based self-administered survey, was adapted (with permission) from a survey tool previously used by the American Pharmacists Association incorporating input from Canadian experts in the field and stakeholders using the principles of Dillman.32,33Content validity testing was completed by four reviewers, with expertise in immunization, using a rating worksheet with a four-point content validity index. Questions rated as 1 (not relevant) or 2 (major revisions) were removed and those rated 3 (relevant, minor revision required) or 4 (relevant and succinct) were kept. Test-retest reliability was assessed by five pharmacists completing the survey on two separate occasions, with a correlation co-efficient calculated to compare the two sets of responses. The correlation co-efficient was >0.80, which was determined sufficient to consider the responses as consistent.
The web-based questionnaire was sent via email to NB pharmacists via the New Brunswick Pharmacists’ Association (NBPA) between April and June 2014. The email contained a detailed information letter and direct link to the web-based survey. Eligible participants had to be licensed pharmacists in NB working either full- or part-time in a clinical pharmacy setting (community pharmacy, ambulatory clinic or hospital). Two reminder letters were sent via email by NBPA at weekly intervals to improve the survey response rate. All surveys were completed via Opinio software.34The final survey took approximately 30 minutes to complete, though participants had the option to save their progress and complete the survey later. All contact with pharmacists was directly via NBPA. Survey participants remained anonymous, and no personal identifiers were collected.
This study was approved by the Research Ethics Board of the Capital District Health Authority (File #CDHA-RS/2014-035 approved May 14, 2013). All research was performed in accordance with relevant guidelines and regulations.
Survey
The survey consisted of a total of 41 questions within the following five domains: 1) demographic information, including primary practice setting and years of practice; 2) immunization training status, confidence in providing immunizations, personal immunization status, and attitudes towards vaccine safety and importance; 3) immunization services offered by their practice site, vaccines provided, and perceptions of barriers to provision of immunization services; 4) immunization services provided by the individual pharmacist; and 5) reimbursement and perception of acceptance as an immunization provider.
Likert scales were a 5-point scale that ranged from Strongly Disagree to Strongly Agree for agreement with statement questions and for frequency of activity questions, the options were “Never”, “Rarely”, “Sometimes”, Often”, and “Always”. A copy of the survey may be obtained by contacting the corresponding author.
Data analysis
Survey data was analyzed using descriptive statistics to identify the general respondent characteristics and frequency of responses. Comparison of continuous variables was done using parametric and non-parametric methods as appropriate based on distribution of the data. Chi-square was used for comparison of categorical variables. All analyses were completed using Excel 2013 version (Microsoft Corporation).
Responses to open-ended questions were read and re-read in order to become familiar with the content. Codes were assigned to segments of the data that were relevant to the research question. An inductive coding process was used that informed development of common themes.
RESULTS
The overall survey response rate was 28% (180/635); however only 168 (26%) were evaluable.Table 1outlines the demographic information of the respondents. The majority (86%, 132/154) reported having received all required adult immunizations and 93% (144/154) reported receipt of the annual influenza vaccine. Of those that responded “yes”; most stated that they received the influenza vaccine to protect their patients, themselves and society. Reasons for responding “no” included personal choice, lack of accessibility, and that they were healthy.
Characteristic | Study result | NB Pharmacist population |
---|---|---|
Number of Pharmacists | 168 evaluable | 813 (635 members of NBPA at the time of the survey) |
Gender | ||
Male | 34.7% | 33.7% |
Female | 65.3% | 66.3% |
Agea | ||
<30 | 17.3% | 18.6% |
30-39 | 28.6% | 28.5% |
40-49 | 28.6% | 27.6% |
50-59 | 19.6% | 20% |
60+ | 5.9% | 5.4% |
Years Practicingb | ||
0-9 | 35.2% | 37% |
10-19 | 20.8% | 26.3% |
>20 | 44% | 36.6% |
Primary Position | ||
Staff pharmacist | 52.8% | 65.4% |
Owner/Manager | 39.6% | 28% |
Practice Setting (community) | 89.9% | 75.1% |
aCIHI data provided in bands
bNote, slight differences in ranges of years, CIHI data provided 0 to 10 years and 11 to 20, and <20, this survey was survey was 0 to 9 years and 10 to 19 years, and 20 years or more
Approximately 93% of respondents indicated that they had completed an injection training program with over 90% of those who completed a program responding that they felt “confident” or “very confident” in providing immunizations based on the training they acquired. When respondents were asked to provide suggestions for additional content that should be included in the online modules and the live day training, the most common responses were for more information on the management of adverse events following immunization, as well as additional information on providing immunizations to special populations (e.g. immunocompromised individuals and travelers), and further reinforcement of general administration practices, such as selecting needle gauge and length for patients of various sizes and ages.
Over 93% of respondents indicated that they currently administer vaccines in their practice with nearly 80% of them providing immunizations “often” or “always”. Most patients immunized by pharmacists were adults 18 years of age and older with respondents indicating less than 20% (on average) of vaccines administered were to those less than 18 years of age. Approximately 27% of respondents were immunizing for 1 year or less, 49% for 1 to 3 years and 25% for over 3 years. The number and type of vaccines administered in the last year varied between respondents (Table 2andTable 3). Of the estimated 15,000 vaccines administered based on self-reporting by respondents since they began immunizing, seven adverse events were reported, 6 were vasovagal and 1 was suspected anaphylaxis. All were managed appropriately based on the written responses.
Vaccine | Num. Administering / respondents |
---|---|
Hepatitis A | 115 / 117 |
Influenza | 117 / 120 |
Hepatitis B | 114 / 117 |
Herpes zoster | 91 / 120 |
Human papillomavirus | 62 / 120 |
Travel vaccines | 43 / 116 |
Pneumococcal | 31 / 117 |
Tetanus (Td, Tdap) | 21 / 113 |
Meningococcal | 16 / 116 |
The majority of respondents (>80%) were comfortable or very comfortable initiating conversations with patients about receiving influenza, herpes zoster, hepatitis A or hepatitis B vaccines but less comfortable discussing other vaccines, including pneumococcal, tetanus and meningococcal. The reasons most often cited for why they were uncomfortable were: lack of knowledge of the vaccine, reimbursement concerns, being unsure if it is a required vaccine, and being unsure about safety in different patient populations.
Most respondents felt fully accepted as immunization providers by patients, with about 97% reporting agreement or strong agreement, as well as most reporting frequent request for vaccine information or advice (Table 4). Seventy percent or more agreed or strongly agreed that they had been fully accepted as an immunization provider by local physicians and health departments. Referrals from other providers were reported by many respondents, with 85% indicating referrals from physicians, 43% reported referrals from nurses, and 32% indicated referrals from public health.
Survey respondents were asked to identify barriers they perceived to providing immunization services from a list of possible barriers, in which they could check all that they felt applied, as well as the option to write-in additional barriers, which are presented inTable 5. Four key barriers identified through quantitative (Figure 4) and qualitative responses (not shown) were: 1) concern about reimbursement, 2) lack of a universal influenza program (reimbursement concerns), 3) insufficient staffing and 4) lack of space for vaccine administrations within the pharmacy.
Barrier | % |
---|---|
Reimbursement concerns | 66 |
Lack of universal influenza vaccination | 44 |
Insufficient staffing | 42 |
Lack of space for administration | 23 |
Record keeping | 11 |
Lack of support from physicians | 11 |
Lack of space for vaccination storage | 10 |
Time for certification | 10 |
Managing adverse effects | 9 |
Liability concerns | 9 |
Cost of certification | 7 |
Unable to recognize adverse effects | 6 |
Lack of support from management | 5 |
Note: total number of responses greater than N, as respondents could choose all that applied
Comparisons of immunizers versus non-immunizers were not possible due to very few respondents identifying as non-immunizers. Comparisons were made between respondents in practice less than 10 years versus those greater than 10 years. Those practicing less than 10 years were less likely to have concerns about staffing as a barrier (27% versus 45%, p=0.03) and were also more likely to have been immunizing for longer than 24 months (78% versus 49%, p=0.003).
When asked what was needed to expand immunization services in their practice, respondents’ answers were classified according to four categories: scope of practice; logistics; promotion; and training. Regarding scope of practice, many open-ended responses related to the issue that pharmacists should be able to administer all vaccines that are recommended in the publicly funded programs, not just influenza (at least for those individuals 5 years of age and older) and that they should be able to provide them through provincial funding like physicians, who administer most vaccines within the publicly funded systems, and public health, who focus their immunization services to areas where there is a shortage of primary care providers. Some also conveyed that travel vaccines, including yellow fever should also be provided in pharmacies. When discussing logistics, many spoke of the need to have adequate staffing, space, refrigerators and other supplies and equipment, and access to health and vaccine records. Adequate reimbursement was also a major issue raised by respondents. This included providing publicly funded vaccines free of charge and providing an administration fee for those vaccines so that the cost to the consumer would be no different in a pharmacy than in a physician’s office. Lack of public awareness was considered an issue with the suggestion that more promotion to the public about the availability of vaccines in pharmacies and the capabilities of the pharmacists be a priority. Promotion to physicians of the benefits of pharmacists providing vaccines and the likelihood that this would not compete with physicians’ practices was also considered to be valuable. Continued and ongoing training of pharmacists was felt to be important including both vaccine information, but also practical issues including needle size, gauge, and landmarking. A centrally maintained information website by pharmacists for pharmacists was also thought to be useful. Training of pharmacy technicians was also seen by many as an essential step since they are critical to the proper patient flow and they are not currently involved in vaccine training.
DISCUSSION
This study explored immunization-related activities and perceived barriers to providing immunization services of pharmacists in New Brunswick, Canada within the first five years of legislative changes allowing them to immunize. Most respondents were administering immunizations, providing a variety of vaccines, with the most common being influenza, hepatitis A and hepatitis B, mainly to adults 18 years of age and older. Most felt accepted as immunizers by patients and other providers, but identified several barriers, with reimbursement concerns, lack of staff and space restrictions as the most frequently cited obstacles to providing or expanding immunization services. Reported barriers were similar between survey responses and open-ended questions. These data are consistent with those reported by others, where lack of reimbursement by third party payers for vaccines administered in the pharmacy setting was identified as an important challenge in the provision of immunization services.26,36-38This includes the lack of a publicly funded universal influenza immunization program and lack of access to other publicly funded vaccines for adults, such as pneumococcal polysaccharide vaccine. Likewise, lack of staff or time and space restrictions were found to be common concerns.26,36,37,38
Seasonal influenza vaccine for high risk individuals is the only vaccine for which NB pharmacists are reimbursed within the publicly funded immunization program, so it is not surprising that this was the most frequently administered vaccine.39Respondents also reported frequent administration of vaccines outside of the publicly funded program (Hepatitis A and B, either as a single vaccine or in combination), likely administered for travel and would be paid out of pocket or by private insurance. Likewise, herpes zoster, also privately funded, was common. Unlike many US jurisdictions, pneumococcal vaccine was not a commonly administered vaccine, probably due to lack of reimbursement through the publicly funded system.37
Like another Canadian study, we found that the majority of respondents have received all required adult immunizations and the annual influenza vaccine.40High immunization coverage in pharmacists offers protection to patients and if they are supporters of immunization for themselves, it is more likely that they will be strong advocates for immunizing their patients.41,42,43
The majority of respondents felt that they have been fully accepted as immunizers by patients and other providers, which was further supported by how often they indicated they received referrals from other providers. Similar results were seen in a national survey of the public and healthcare providers on the potential role of pharmacists as immunizers.44,45Despite these positive responses, several concerns were identified around the lack of awareness of the role pharmacists can take in provision of immunizations by various groups, including the public and physicians. Despite some successes, a public relations campaign and targeted efforts with other healthcare providers may be required for full acceptance of pharmacists as immunizers.
Interestingly those practicing less than 10 years, had less concerns about staffing and were immunizing longer than their counterparts in practice greater than 10 years. It is not known whether newer practitioners were more interested in embracing expanded scope of practice or if they felt more pressure to obtain immunization training to obtain and maintain professional employment. This was observed in a recent qualitative study, in which respondents felt compelled to become certified and provide immunizations for employment.46
Many concerns have been raised by other providers about the potential issues around pharmacist management of adverse events following immunization.47,48The responses to this study offer further support for the capabilities of pharmacists in this area, as very few identified management of adverse events as a potential barrier, although many did note interest in having more training provided around management of adverse events, and for those that had a patient experience a reaction following immunization, managed it appropriately.
The barriers most frequently identified to providing immunizations were concerns around reimbursement (including, lack of a universally funded influenza vaccination program), insufficient staff and lack of space in the pharmacy. Unfortunately, due to current funding models and limitations within healthcare budgets, these barriers are unlikely to be resolved quickly. Of note, these barriers were also identified in other jurisdictions, adding further support to the barriers identified in this study having applicability across jurisdictions.28,49
Strengths of this study included the development and testing of the questionnaire, which included permitted use of questions from a previously used questionnaire that were adapted for the jurisdiction, discussion with stakeholders on information that would be valuable, and content validity testing, and test-retest reliability prior to deployment. In addition, this study provides the perspective of pharmacists who were newly immunizing in a country with universal health coverage that may provide insight to other similar jurisdictions looking to add this to pharmacist scope of practice.
Although the response rate was lower than anticipated, it was over 20% and our sample appears representative of the pharmacist population in NB with respect to gender and age distribution at the time of the survey.35The distribution of number of years practicing is similar between our respondents and CIHI data, despite differences in the ranges available (e.g. 0 to 9 years versus 0 to 10 years).35Differences were seen in the primary position with our study having more respondents who identified as owners or managers compared to the CIHI data for the province. We also had more respondents indicate a community practice setting than the CIHI results. This may be due to the fax reminder sent to pharmacies about the survey from the New Brunswick Pharmacists’ Association. The reminders were focused on community pharmacies and it is possible that more managers and owners were responsible for reviewing faxes received and subsequently more likely to respond. In addition, staff pharmacists may not have had time to fill out the questionnaire during their shift and may not have been willing to do it during off hours. We also anticipated more responses from community pharmacists, as immunizing by pharmacists is primarily completed in the community setting in NB. It is possible that managers and owners may perform different immunizing behaviours and have different concerns (such as reimbursement) than staff pharmacists; however, we are unable to determine what these differences may be. Our response rate however was higher than others recently completed (~18-19%) with pharmacists in Canada around scope of practice or immunization status.29,40An additional limitation was the number of surveys without sufficient responses to be evaluable. As this was the first study of its kind in Canada, it was long, to ensure it captured the breadth and depth of pertinent areas of immunization practice. Despite the length and number of incomplete questionnaires, a sufficient number were evaluable to allow a response rate greater than 25%.
CONCLUSIONS
Pharmacists in New Brunswick, Canada are actively participating in the provision of a variety of immunizations, beyond influenza vaccines, including hepatitis A and B, and herpes zoster. They felt strongly supported by patients and other healthcare providers. The main barriers identified included the lack of a universally funded influenza immunization program, insufficient staffing and space, and concerns around reimbursement for services. The results of this study may provide insight to other jurisdictions considering expanding the role of pharmacists as immunizers. Future work will include development of strategies to overcome identified barriers, in consultation with stakeholders, and evaluation of implementation of strategies. Additionally a replication study may be completed to assess changes in practice over time.